Therefore, the KRAS mutations in our clinical PDAC samples were verified in-house by Sanger sequencing, and analysis of the samples by immunohistochemistry (IHC) showed an increase in microlymphatic vessels in the KRASG12D PDAC tissues as compared with cancer tissues with other KRAS subtypes (Figure 1, A–C). The gene discussed is KRAS; the disease is cancer.